Beom-Jun Kim1, Yumie Rhee2, Chong Hwa Kim3, Ki Hyun Baek4, Yong-Ki Min5, Deog-Yoon Kim6, Seong Hee Ahn1, Hyeonmok Kim1, Seung Hun Lee1, Sun-Young Lee7, Moo-Il Kang8, Jung-Min Koh9. 1. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea. 2. Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea. 3. Department of Internal Medicine, Sejong General Hospital, Bucheon 422-711, Republic of Korea. 4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul 137-701, Republic of Korea. 5. Division of Endocrinology and Metabolism, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea. 6. Department of Nuclear Medicine, Kyunghee University School of Medicine, Seoul 130-872, Republic of Korea. 7. Asan Institute for Life Sciences, Seoul 138-736, Republic of Korea. 8. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul 137-701, Republic of Korea. Electronic address: mikang@catholic.ac.kr. 9. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea. Electronic address: jmkoh@amc.seoul.kr.
Abstract
BACKGROUND: Periostin is preferentially expressed by the periosteum, which mainly covers the long bones. Therefore, the role of periostin in osteoporotic fracture (OF) may differ depending on bone type. We performed a case-control study to investigate whether periostin can serve as a predictor of OF risk, particularly after dividing OFs into non-vertebral and vertebral fractures. METHODS: Among 532 consecutive postmenopausal women not taking any drug or without any disease that could affect bone metabolism, 133 cases with OF (i.e., non-vertebral and/or vertebral fractures) and 133 age- and body mass index-matched controls were enrolled. Non-vertebral (i.e., forearm, humerus, hip, and pelvis; n=81) and morphological vertebral (n=62) fractures were identified by an interviewer-assisted questionnaire and lateral thoracolumbar radiographs, respectively. Bone mineral density (BMD) and plasma periostin levels were also measured. RESULTS: Plasma periostin was markedly higher in subjects with non-vertebral fracture than their controls even after adjustment for BMD and potential confounders (P=0.006). Each standard deviation increment of plasma periostin was associated with a multivariable-adjusted odds ratio of 1.59 for non-vertebral fracture. The odds for non-vertebral fracture were 2.48-fold higher in subjects in the highest periostin tertile compared with those in the lowest periostin tertile (95% confidence interval=1.10-5.61). However, associations between plasma periostin and vertebral fracture were not observed, regardless of the adjustment model used. Consistently, plasma periostin levels were inversely associated with proximal femur BMD (P=0.007 to 0.030) but not lumbar spine BMD. In subgroup analyses, plasma periostin had no correlation with the levels of classical bone turnover markers. CONCLUSIONS: Plasma periostin may be a potential biomarker of the risk of OF, especially in non-spinal skeletal sites, such as the limbs, rather than spine.
BACKGROUND:Periostin is preferentially expressed by the periosteum, which mainly covers the long bones. Therefore, the role of periostin in osteoporotic fracture (OF) may differ depending on bone type. We performed a case-control study to investigate whether periostin can serve as a predictor of OF risk, particularly after dividing OFs into non-vertebral and vertebral fractures. METHODS: Among 532 consecutive postmenopausal women not taking any drug or without any disease that could affect bone metabolism, 133 cases with OF (i.e., non-vertebral and/or vertebral fractures) and 133 age- and body mass index-matched controls were enrolled. Non-vertebral (i.e., forearm, humerus, hip, and pelvis; n=81) and morphological vertebral (n=62) fractures were identified by an interviewer-assisted questionnaire and lateral thoracolumbar radiographs, respectively. Bone mineral density (BMD) and plasma periostin levels were also measured. RESULTS: Plasma periostin was markedly higher in subjects with non-vertebral fracture than their controls even after adjustment for BMD and potential confounders (P=0.006). Each standard deviation increment of plasma periostin was associated with a multivariable-adjusted odds ratio of 1.59 for non-vertebral fracture. The odds for non-vertebral fracture were 2.48-fold higher in subjects in the highest periostin tertile compared with those in the lowest periostin tertile (95% confidence interval=1.10-5.61). However, associations between plasma periostin and vertebral fracture were not observed, regardless of the adjustment model used. Consistently, plasma periostin levels were inversely associated with proximal femur BMD (P=0.007 to 0.030) but not lumbar spine BMD. In subgroup analyses, plasma periostin had no correlation with the levels of classical bone turnover markers. CONCLUSIONS: Plasma periostin may be a potential biomarker of the risk of OF, especially in non-spinal skeletal sites, such as the limbs, rather than spine.
Authors: Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: J Yan; H J Liu; H Li; L Chen; Y Q Bian; B Zhao; H X Han; S Z Han; L R Han; D W Wang; X F Yang Journal: Osteoporos Int Date: 2017-04-05 Impact factor: 4.507
Authors: Pelin O Simsek Kiper; Hiroaki Saito; Francesca Gori; Andrea Superti-Furga; Roland Baron; Sheila Unger; Eric Hesse; Kei Yamana; Riku Kiviranta; Nicolas Solban; Jeff Liu; Robert Brommage; Koray Boduroglu; Luisa Bonafé; Belinda Campos-Xavier; Esra Dikoglu; Richard Eastell; Fatma Gossiel; Keith Harshman; Gen Nishimura; Katta M Girisha; Brian J Stevenson; Hiroyuki Takita; Carlo Rivolta Journal: N Engl J Med Date: 2016-06-30 Impact factor: 91.245
Authors: E Terpos; D Christoulas; E Kastritis; T Bagratuni; M Gavriatopoulou; M Roussou; A Papatheodorou; E Eleutherakis-Papaiakovou; N Kanellias; C Liakou; I Panagiotidis; M Migkou; P Kokkoris; L A Moulopoulos; M A Dimopoulos Journal: Blood Cancer J Date: 2016-10-07 Impact factor: 11.037
Authors: Yingchang Lu; Latchezar Dimitrov; Shyh-Huei Chen; Lawrence F Bielak; Joshua C Bis; Mary F Feitosa; Lingyi Lu; Maryam Kavousi; Laura M Raffield; Albert V Smith; Lihua Wang; Stefan Weiss; Jie Yao; Jiaxi Zhu; Elias F Gudmundsson; Valborg Gudmundsdottir; Daniel Bos; Mohsen Ghanbari; M Arfan Ikram; Shih-Jen Hwang; Kent D Taylor; Matthew J Budoff; Gauti K Gíslason; Christopher J O'Donnell; Ping An; Nora Franceschini; Barry I Freedman; Yi-Ping Fu; Xiuqing Guo; Gerardo Heiss; Sharon L R Kardia; James G Wilson; Carl D Langefeld; Ulf Schminke; André G Uitterlinden; Leslie A Lange; Patricia A Peyser; Vilmundur G Gudnason; Bruce M Psaty; Jerome I Rotter; Donald W Bowden; Maggie C Y Ng Journal: Circ Genom Precis Med Date: 2021-07-09